Nevro price target lowered to $57 from $68 at Canaccord

Canaccord analyst William Plovanic lowered the firm’s price target on Nevro to $57 from $68 and keeps a Buy rating on the shares. The firm said with the sales organization overhaul, management is messaging it will likely take six to nine months for sales reps to become productive again.